Trevi Therapeutics, Inc. (TRVI) Financial Statements
Free cash flow over the same period: -$52.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TRVITrevi Therapeutics, Inc.Follow TRVI — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Research & development | 19.3 | 22.3 | 23.0 | 19.8 | 23.7 | 39.4 | 33.5 | 41.4 | |
| Operating income | -26.6 | -32.5 | -32.5 | -29.9 | -33.9 | -51.5 | -49.3 | -59.6 | |
| Pre-tax income | -26.1 | -32.8 | -34.0 | -29.2 | -29.1 | -47.9 | -42.8 | -51.2 | |
| Income tax | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.1 | -0.1 | |
| Net income | -26.1 | -32.8 | -33.9 | -29.2 | -29.1 | -47.9 | -42.8 | -51.1 | |
| Diluted EPS ($) | -2.28 | -1.81 | -1.49 | -0.45 | -0.29 | -0.47 | -0.32 | -0.33 | |
| Diluted shares (mn) | — | — | — | 64.5 | 99.0 | 102.0 | 134.7 | — |
USD millions · SEC XBRL
Trevi Therapeutics, Inc. — questions
- What is Trevi Therapeutics, Inc.'s net income?
- -$51.1M over the twelve months to 2026-06-30.
- What is Trevi Therapeutics, Inc.'s free cash flow?
- -$52.9M over the twelve months to 2026-06-30.
- What are Trevi Therapeutics, Inc.'s diluted earnings per share?
- $-0.33 over the twelve months to 2026-06-30.
Every figure on this page comes from Trevi Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.